MLTX

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing nanobody-based therapies for inflammatory diseases. The company's lead candidate targets IL-17A and IL-17F cytokines, aiming to treat conditions such as hidradenitis suppurativa, psoriatic arthritis, and psoriasis. MoonLake leverages its Nanobody technology platform for novel therapeutic approaches.